Precision oncology therapies that target genomic drivers of cancer are advancing at a rapid pace, yet the use of highly accurate molecular diagnostic solutions remains limited in community and regional settings where approximately 85 percent of cancer patients receive care.1
ArcherDX is developing and seeking regulatory clearances for next-generation sequencing (NGS) diagnostics to help solve for the underutilization of targeted cancer therapies.
Results from centralized genomic tests can take well over 20 days to be returned, depending on complexity and sample type.6 Our products enable local testing with potential times to run the test as short as 3 to 5 days, accelerating time to results while also allowing the original clinical researcher to maintain sample custody.7
Investigational products to enable testing across a multitude of input types with flexibility to analyze DNA, RNA and ctDNA from blood or tissue in order to provide higher resolution and a more comprehensive view of variations.3,4,5
ArcherDX is developing genomic diagnostic options designed to enable use in community and regional settings where there is a lack of infrastructure and expertise to implement sophisticated genomic analysis.